Search
Displaying results 641 to 650 of 682.
Single-cell Analysis
Pathogenic bacteria can reside in a mammalian host for a life-long period and chronic carriers form a reservoir leading to recurrent infections. Despite the importance of chronic infections for public health, how a subset of pathogens escape the host’s immune surveillance and how the host contains the spread of bacteria are still poorly understood. Scientists within the Single-Cell Analysis group develop and use single-cell transcriptomics and computational approaches to decipher the microenvironments of individual pathogens and ultimately their functional consequences on infection outcome. This group is located at the Helmholtz Institute for RNA-based Infection Research (HIRI).
Dynamics of Respiratory Infections
Several chronic inflammatory diseases of the lung have been recently associated with alterations in the composition of the airway microbiome. Moreover, the lung microbiota can be classified according to its predominance either of proinflammatory bacteria, such as strains from the genera S taphylococcus, Pseudomonas , and Haemophilus or of low-stimulatory bacteria from genera like Prevotella, Streptococcus , and Veillonella . Moreover, it is already known that the commensal lung microbiota can influence host immune system activation by producing numerous structural ligands and metabolites such as lipopolysaccharide, peptidoglycan, and secondary metabolites. However, the interaction between the lung microbiota and the airway epithelium, as well as their interactions with pulmonary pathogens, are not well understood.
Flow Cytometry and Cell Sorting
Our organism is made of many different cells that are specialized to perform specific tasks. As long as they work together in the collective, we will stay healthy – do they change or are they changed by pathogens, we become unbalanced and sick. The Flow Cytometry and Cell Sorting platform provides the instrumentation and expert knowledge for the phenotypic identification and functional analysis of cells at the single cell level.
Compound Profiling and Screening
The World Health Organization (WHO) considers the spread of microorganisms which are resistant to the most common antibiotics an increasing threat to the well-being of the world population. Not only is the number of patients increasing whose infectious disease can no longer be treated, but also in some circumstances patients with other severe diseases will not be treated if the therapy is accompanied with suppression of the immune system and thus, an increased risk of infection. Thus, new active agents for the treatment of infectious diseases are urgently needed, as well as the responsible use of existing antibiotics. Prerequisites for the discovery of new drugs are relevant biological screening assays together with compound libraries of broad chemical diversity. We perform primary screens, based either on own protocols or on protocols developed by cooperation partners and transferred to our infrastructure. In cooperation with partners we also perform secondary assays to optimize first primary hits.
Chemical Biology of Carbohydrates
Carbohydrates and glycoconjugates belong to the three major classes of biopolymers. Complex carbohydrates play important roles in biological recognition processes that are represented by the presence of dense glycoconjugate layers on cells known as the glycocalyx. Despite their importance, the study of carbohydrates suffers from limited methods for their synthesis and analysis contrary to nucleic acids or proteins. This group is located at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS).
Chemical Biology
In their ongoing quest for new therapies against pathogens, scientists are focusing primarily on chemical agents. Discovering new bioactive compounds, characterising their functionality and optimising their properties are the three main goals of the Department of Chemical Biology (CBIO) at the HZI.
Biomarkers of Infectious Diseases
The Research Group Biomarkers of Infectious Diseases aims to identify more accurate diagnostic, prognostic and predictive host biomarkers for infectious diseases and the vaccine response. The clinical aims of the group are to help select the most effective, individualized treatment as early as possible, aiming to streamline the use of anti-infectives (improve anti-infective stewardship) and to improve clinical outcome. This group is located at the TWINCORE in Hannover.
Biological Barriers and Drug Delivery
While considering the confusing flood of drugs in the pharmacies it is hard to believe in a lack of medication. But there are still many infectious diseases and also cancer that cannot be treated sufficiently. During a medical treatment it is essential that the drug arrives at the envisaged body region. Read more about the research of the department “Biological Barriers and Drug Delivery” on techniques for the correct distribution of novel drugs. This group is located at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) .
Computational Biology for Individualised Medicine
Infections are among the biggest threats to health and the most significant causes of death worldwide. Our aim is to reveal the host genetic risk factors and their downstream molecular pathways, which are crucial to make progress in understanding and treating infectious diseases in an individualised manner as well as to improve the identification of patients at risk. The department is part of the developing CiiM and currently housed at the TWINCORE in Hannover.
Antiviral and Antivirulence Drugs
Work in the Empting lab focuses on tackling innovative and difficult-to-address anti-infective targets such as bacterial virulence regulatory systems as well as un(der)explored anti-herpesviral persitance mediators. By this, we aspire to circumvent common resistance mechanisms and to refill the dried out development pipeline. This group is located at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)
